BR0016395B1 - Derivados de adamantano - Google Patents

Derivados de adamantano

Info

Publication number: BR0016395B1
Authority: BR; Brazil
Prior art keywords: adamantane derivatives; adamantane; derivatives
Prior art date: 1999-12-17

Application number

BRPI0016395-3B1A

Other languages

English (en)

Other versions

BRPI0016395B8 (pt

BR0016395A (pt

Inventor

Lilian Alcaraz

Moya Caffrey

Mark Furber

Timothy Luker

Michael Mortimore

Austen Pimm

Phillip Thorne

Paul Willis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-17

Filing date

2000-12-12

Publication date

2013-10-08

1999-12-17 Priority claimed from SE9904651A external-priority patent/SE9904651D0/xx

2000-06-27 Priority claimed from GB0015744A external-priority patent/GB0015744D0/en

2000-07-22 Priority claimed from GB0017942A external-priority patent/GB0017942D0/en

2000-12-12 Application filed filed Critical

2002-08-27 Publication of BR0016395A publication Critical patent/BR0016395A/pt

2013-10-08 Publication of BR0016395B1 publication Critical patent/BR0016395B1/pt

2021-05-25 Publication of BRPI0016395B8 publication Critical patent/BRPI0016395B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Cardiology (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Communicable Diseases (AREA)
Obesity (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Endocrinology (AREA)

BRPI0016395A 1999-12-17 2000-12-12 derivados de adamantano BRPI0016395B8 (pt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
SE9904651A SE9904651D0 (sv)	1999-12-17	1999-12-17	Novel compounds
GB0015744A GB0015744D0 (en)	2000-06-27	2000-06-27	Novel compounds
GB0017942A GB0017942D0 (en)	2000-07-22	2000-07-22	Novel compounds
PCT/SE2000/002505 WO2001044170A1 (en)	1999-12-17	2000-12-12	Adamantane derivatives

Publications (3)

Publication Number	Publication Date
BR0016395A BR0016395A (pt)	2002-08-27
BR0016395B1 true BR0016395B1 (pt)	2013-10-08
BRPI0016395B8 BRPI0016395B8 (pt)	2021-05-25

Family

ID=27255782

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0016395A BRPI0016395B8 (pt)	1999-12-17	2000-12-12	derivados de adamantano

Country Status (32)

Country	Link
US (5)	US6881754B2 (pt)
EP (5)	EP1352896B1 (pt)
JP (2)	JP3710418B2 (pt)
KR (2)	KR20070012883A (pt)
CN (1)	CN1312120C (pt)
AR (1)	AR035325A1 (pt)
AT (4)	ATE261933T1 (pt)
AU (2)	AU780506B2 (pt)
BR (1)	BRPI0016395B8 (pt)
CA (1)	CA2393352C (pt)
CO (1)	CO5251381A1 (pt)
CY (3)	CY1106357T1 (pt)
CZ (1)	CZ20022093A3 (pt)
DE (4)	DE60032823T2 (pt)
DK (4)	DK1352896T3 (pt)
EE (1)	EE05134B1 (pt)
ES (4)	ES2215777T3 (pt)
HK (1)	HK1046678B (pt)
HU (1)	HUP0300616A3 (pt)
IL (2)	IL150124A0 (pt)
IS (1)	IS2246B (pt)
MX (1)	MXPA02005789A (pt)
MY (1)	MY125978A (pt)
NO (1)	NO328682B1 (pt)
NZ (1)	NZ519378A (pt)
PL (1)	PL200836B1 (pt)
PT (4)	PT1352897E (pt)
SI (1)	SI1352895T1 (pt)
SK (1)	SK286987B6 (pt)
TR (1)	TR200401432T4 (pt)
TW (1)	TWI258462B (pt)
WO (1)	WO2001044170A1 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9904505D0 (sv)	1999-12-09	1999-12-09	Astra Pharma Prod	Novel compounds
TWI258462B (en) *	1999-12-17	2006-07-21	Astrazeneca Ab	Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904738D0 (sv)	1999-12-22	1999-12-22	Astra Pharma Prod	Novel compounds
PA8557501A1 (es)	2001-11-12	2003-06-30	Pfizer Prod Inc	Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en)	2001-11-12	2003-05-22	Pfizer Products Inc.	N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0200920D0 (sv) *	2002-03-25	2002-03-25	Astrazeneca Ab	Novel compounds
US7071223B1 (en)	2002-12-31	2006-07-04	Pfizer, Inc.	Benzamide inhibitors of the P2X7 receptor
PA8591801A1 (es)	2002-12-31	2004-07-26	Pfizer Prod Inc	Inhibidores benzamidicos del receptor p2x7.
SE0300445D0 (sv) *	2003-02-18	2003-02-18	Astrazeneca Ab	New combination
SE0300480D0 (sv) *	2003-02-21	2003-02-21	Astrazeneca Ab	Novel compounds
MXPA05012086A (es) *	2003-05-12	2006-02-22	Pfizer Prod Inc	Inhibidores de benzamida del receptor p2x7.
US20070010497A1 (en) *	2003-05-29	2007-01-11	Nigel Boughton-Smith	Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
TW200507829A (en) *	2003-05-29	2005-03-01	Astrazeneca Ab	New combination
EP1644042A1 (en) *	2003-05-29	2006-04-12	AstraZeneca AB	A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
SE0302192D0 (sv) *	2003-08-08	2003-08-08	Astrazeneca Ab	Novel compounds
SE0302488D0 (sv) *	2003-09-18	2003-09-18	Astrazeneca Ab	New combination
WO2006003517A1 (en) *	2004-06-29	2006-01-12	Warner-Lambert Company Llc	Combination therapies utilizing benzamide inhibitors of the p2x7 receptor
EP1776352A1 (en) *	2004-06-29	2007-04-25	Pfizer Products Inc.	Method for preparing 5-[4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3h[1,2,4]triazin-2-yl]-benzamide derivatives by deprotecting the hydroxyl-protected precursers
SA05260265A (ar) *	2004-08-30	2005-12-03	استرازينيكا ايه بي	مركبات جديدة
US20060063834A1 (en) *	2004-09-09	2006-03-23	Frangioni John V	Substituted adamantanes, and methods of making the same
SE0402925D0 (sv) *	2004-11-30	2004-11-30	Astrazeneca Ab	Novel Compounds
US20080207577A1 (en) *	2005-07-11	2008-08-28	Astrazeneca Ab	Combination I
WO2007008157A1 (en) *	2005-07-11	2007-01-18	Astrazeneca Ab	New combination 2
TW200819416A (en) *	2006-09-05	2008-05-01	Astrazeneca Ab	Novel process 470
PT2242759E (pt)	2008-02-06	2012-12-17	Astrazeneca Ab	Compostos
NZ587799A (en)	2008-03-25	2012-06-29	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
EP2243772B1 (en)	2009-04-14	2012-01-18	Affectis Pharmaceuticals AG	Novel P2X7R antagonists and their use
GB2469915A (en) *	2009-04-30	2010-11-03	Astrazeneca Ab	2-chloro-5-[3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec- 1-ylmethyl)-benzamide hydrochloride salt
GB0913342D0 (en)	2009-07-31	2009-09-16	Astrazeneca Ab	Compounds - 801
EP2322149A1 (en)	2009-11-03	2011-05-18	Universidad del Pais Vasco	Methods and compositions for the treatment of ischemia
CN102858741A (zh)	2010-05-14	2013-01-02	阿费克蒂斯制药股份公司	制备p2x7r拮抗剂的新方法
JP2013249256A (ja) *	2010-09-15	2013-12-12	Astellas Pharma Inc	脂肪性肝疾患治療薬
WO2012110190A1 (en)	2011-02-17	2012-08-23	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
WO2012163792A1 (en)	2011-05-27	2012-12-06	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
WO2012163456A1 (en)	2011-05-27	2012-12-06	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
CN103687860B (zh)	2011-07-22	2016-06-08	埃科特莱茵药品有限公司	作为p2x7受体拮抗剂的杂环酰胺衍生物
BR112014017735B1 (pt)	2012-01-20	2022-06-28	Idorsia Pharmaceuticals Ltd	Compostos derivados de amida heterocíclicos como antagonistas do receptor de p2x7, composição farmacêutica, e, uso de um composto
JP6295269B2 (ja)	2012-12-12	2018-03-14	イドーシアファーマシューティカルズリミテッドＩｄｏｒｓｉａＰｈａｒｍａｃｅｕｔｉｃａｌｓＬｔｄ	Ｐ２ｘ７受容体アンタゴニストとしてのインドールカルボキサミド誘導体
JP6295270B2 (ja)	2012-12-18	2018-03-14	イドーシアファーマシューティカルズリミテッドＩｄｏｒｓｉａＰｈａｒｍａｃｅｕｔｉｃａｌｓＬｔｄ	Ｐ２ｘ７受容体アンタゴニストとしてのインドールカルボキサミド誘導体
US9388198B2 (en)	2013-01-22	2016-07-12	Actelion Pharmaceuticals Ltd.	Heterocyclic amide derivatives as P2X7 receptor antagonists
ES2616114T3 (es)	2013-01-22	2017-06-09	Actelion Pharmaceuticals Ltd.	Derivados de amida heterocíclica como antagonistas del receptor P2X7
EP4479366A2 (en) *	2022-02-15	2024-12-25	The Children's Medical Center Corporation	Compositions and methods relating to atp/p2x7r signaling inhibition
EP4230196A1 (en)	2022-02-21	2023-08-23	Som Innovation Biotech, S.A.	Compounds for use in the treatment of dystrophinopathies
WO2025024881A1 (en) *	2023-07-28	2025-02-06	The University Of Sydney	Adamantyl p2x7 receptor antagonists and their use in the treatment of cardiovascular diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3029241A (en) *		1962-04-10		Phenylpbperazinylacyl anilines
US3464998A (en) *	1968-03-04	1969-09-02	Searle & Co	Adamantyl esters and amides of pyridinecarboxylic acids
US3732305A (en) *	1970-03-03	1973-05-08	Us Army	S-substituted thiosulfuric acid derivatives and preparation thereof
US3789072A (en) *	1970-04-22	1974-01-29	Squibb & Sons Inc	Carboxamides
FR2346011A1 (fr)	1976-02-02	1977-10-28	Orsymonde	Acetanilido-piperazines
ZA825719B (en)	1981-09-03	1983-06-29	Recordati Chem Pharm	Alkanoylanilides
CA2015473C (en)	1989-04-28	1998-04-14	Iwao Kinoshita	Triphenylmethane derivatives
US6021024A (en) *	1992-02-21	2000-02-01	Kabushiki Kaisha Toshiba	Magnetic disk drive having a constant skew angle
CA2091194A1 (en)	1992-04-08	1993-10-09	Richard D. Connell	2-oxo-ethyl derivatives as immunosuppressants
ES2125285T3 (es)	1992-07-31	1999-03-01	Bristol Myers Squibb Co	Derivados inhibidores de la reabsorcion de adenosina de difenil-oxazoles, tiazoles e imidazoles.
SG52229A1 (en)	1993-08-10	1998-09-28	Black James Foundation	Gastrin and cck receptor ligands
US5530018A (en) *	1994-02-04	1996-06-25	G. D. Searle & Co.	Meso-azanoradamantanes
GB9409150D0 (en)	1994-05-09	1994-06-29	Black James Foundation	Cck and gastrin receptor ligands
US5912260A (en)	1994-05-27	1999-06-15	James Black Foundation Limited	Gastrin and CCK antagonists
AU701127B2 (en)	1994-10-27	1999-01-21	Merck & Co., Inc.	Muscarine antagonists
DE19608653A1 (de)	1996-03-06	1997-09-11	Thomae Gmbh Dr K	Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
SE9704545D0 (sv) *	1997-12-05	1997-12-05	Astra Pharma Prod	Novel compounds
SE9704544D0 (sv) *	1997-12-05	1997-12-05	Astra Pharma Prod	Novel compounds
WO1999029640A2 (en) *	1997-12-05	1999-06-17	Eisai Co., Ltd.	Compositions and methods for modulating the activity of fibroblast growth factor
SE9704546D0 (sv)	1997-12-05	1997-12-05	Astra Pharma Prod	Novel compounds
US6018089A (en) *	1997-12-09	2000-01-25	Shell Oil Company	Process for separating linear internal olefins from branched internal olefins
WO1999031096A1 (en)	1997-12-18	1999-06-24	Shaman Pharmaceuticals, Inc.	Piperazine derivatives useful as hypoglycemic agents
WO1999059582A1 (en)	1998-05-19	1999-11-25	Centaur Pharmaceuticals, Inc.	Amide therapeutics for the treatment of inflammatory bowel disease
CA2368829A1 (en) *	1999-04-09	2000-10-19	Astrazeneca Ab	Adamantane derivatives
SE9901875D0 (sv)	1999-05-25	1999-05-25	Astra Pharma Prod	Novel compounds
SE9904505D0 (sv)	1999-12-09	1999-12-09	Astra Pharma Prod	Novel compounds
TWI258462B (en) *	1999-12-17	2006-07-21	Astrazeneca Ab	Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904652D0 (sv) *	1999-12-17	1999-12-17	Astra Pharma Prod	Novel Compounds
SE9904738D0 (sv) *	1999-12-22	1999-12-22	Astra Pharma Prod	Novel compounds
GB0013737D0 (en)	2000-06-07	2000-07-26	Astrazeneca Ab	Novel compounds
US6555451B1 (en) *	2001-09-28	2003-04-29	The United States Of America As Represented By The Secretary Of The Navy	Method for making shallow diffusion junctions in semiconductors using elemental doping
SE0103836D0 (sv)	2001-11-16	2001-11-16	Astrazeneca Ab	Novel compounds
SE0200920D0 (sv)	2002-03-25	2002-03-25	Astrazeneca Ab	Novel compounds
SE0300480D0 (sv) *	2003-02-21	2003-02-21	Astrazeneca Ab	Novel compounds
SE0302488D0 (sv)	2003-09-18	2003-09-18	Astrazeneca Ab	New combination
SA05260265A (ar)	2004-08-30	2005-12-03	استرازينيكا ايه بي	مركبات جديدة
SE0402925D0 (sv)	2004-11-30	2004-11-30	Astrazeneca Ab	Novel Compounds

2000
- 2000-12-04 TW TW089125761A patent/TWI258462B/zh not_active IP Right Cessation
- 2000-12-12 CO CO00094336A patent/CO5251381A1/es not_active Application Discontinuation
- 2000-12-12 EP EP03013990A patent/EP1352896B1/en not_active Expired - Lifetime
- 2000-12-12 JP JP2001545259A patent/JP3710418B2/ja not_active Expired - Lifetime
- 2000-12-12 PT PT03013991T patent/PT1352897E/pt unknown
- 2000-12-12 PT PT03013989T patent/PT1352895E/pt unknown
- 2000-12-12 DE DE60032823T patent/DE60032823T2/de not_active Expired - Lifetime
- 2000-12-12 ES ES00986155T patent/ES2215777T3/es not_active Expired - Lifetime
- 2000-12-12 AT AT00986155T patent/ATE261933T1/de active
- 2000-12-12 BR BRPI0016395A patent/BRPI0016395B8/pt not_active IP Right Cessation
- 2000-12-12 KR KR1020077000596A patent/KR20070012883A/ko not_active Ceased
- 2000-12-12 TR TR2004/01432T patent/TR200401432T4/xx unknown
- 2000-12-12 DE DE60009147T patent/DE60009147T2/de not_active Expired - Lifetime
- 2000-12-12 AT AT03013990T patent/ATE376994T1/de active
- 2000-12-12 CN CNB008189226A patent/CN1312120C/zh not_active Expired - Lifetime
- 2000-12-12 AT AT03013989T patent/ATE358117T1/de active
- 2000-12-12 NZ NZ519378A patent/NZ519378A/en not_active IP Right Cessation
- 2000-12-12 ES ES03013989T patent/ES2282546T3/es not_active Expired - Lifetime
- 2000-12-12 SK SK841-2002A patent/SK286987B6/sk not_active IP Right Cessation
- 2000-12-12 EE EEP200200330A patent/EE05134B1/xx not_active IP Right Cessation
- 2000-12-12 PT PT03013990T patent/PT1352896E/pt unknown
- 2000-12-12 PL PL355913A patent/PL200836B1/pl not_active IP Right Cessation
- 2000-12-12 CZ CZ20022093A patent/CZ20022093A3/cs unknown
- 2000-12-12 US US10/149,549 patent/US6881754B2/en not_active Expired - Lifetime
- 2000-12-12 HK HK02108164.1A patent/HK1046678B/en not_active IP Right Cessation
- 2000-12-12 DK DK03013990T patent/DK1352896T3/da active
- 2000-12-12 PT PT00986155T patent/PT1242364E/pt unknown
- 2000-12-12 HU HU0300616A patent/HUP0300616A3/hu unknown
- 2000-12-12 CA CA2393352A patent/CA2393352C/en not_active Expired - Lifetime
- 2000-12-12 IL IL15012400A patent/IL150124A0/xx not_active IP Right Cessation
- 2000-12-12 MX MXPA02005789A patent/MXPA02005789A/es active IP Right Grant
- 2000-12-12 ES ES03013990T patent/ES2294219T3/es not_active Expired - Lifetime
- 2000-12-12 AU AU22444/01A patent/AU780506B2/en not_active Expired
- 2000-12-12 DK DK03013991T patent/DK1352897T3/da active
- 2000-12-12 WO PCT/SE2000/002505 patent/WO2001044170A1/en not_active Ceased
- 2000-12-12 AT AT03013991T patent/ATE350364T1/de active
- 2000-12-12 EP EP03013989A patent/EP1352895B1/en not_active Expired - Lifetime
- 2000-12-12 SI SI200030950T patent/SI1352895T1/sl unknown
- 2000-12-12 EP EP03013991A patent/EP1352897B1/en not_active Expired - Lifetime
- 2000-12-12 DE DE60036968T patent/DE60036968T2/de not_active Expired - Lifetime
- 2000-12-12 ES ES03013991T patent/ES2279031T3/es not_active Expired - Lifetime
- 2000-12-12 KR KR1020027007702A patent/KR100710110B1/ko not_active Expired - Lifetime
- 2000-12-12 DE DE60034155T patent/DE60034155T2/de not_active Expired - Lifetime
- 2000-12-12 EP EP07014968A patent/EP1862451A1/en not_active Withdrawn
- 2000-12-12 EP EP00986155A patent/EP1242364B1/en not_active Expired - Lifetime
- 2000-12-12 DK DK00986155T patent/DK1242364T3/da active
- 2000-12-12 DK DK03013989T patent/DK1352895T3/da active
- 2000-12-15 AR ARP000106695A patent/AR035325A1/es active IP Right Grant
- 2000-12-15 MY MYPI20005926A patent/MY125978A/en unknown
2002
- 2002-05-31 IS IS6406A patent/IS2246B/is unknown
- 2002-06-14 NO NO20022856A patent/NO328682B1/no not_active IP Right Cessation
2004
- 2004-03-31 US US10/813,426 patent/US7132457B2/en not_active Expired - Lifetime
2005
- 2005-05-27 AU AU2005202321A patent/AU2005202321B2/en not_active Ceased
- 2005-06-03 JP JP2005163710A patent/JP2005320340A/ja active Pending
2006
- 2006-09-29 US US11/529,746 patent/US7297818B2/en not_active Expired - Fee Related
2007
- 2007-03-06 CY CY20071100312T patent/CY1106357T1/el unknown
- 2007-05-17 CY CY20071100671T patent/CY1106602T1/el unknown
- 2007-06-20 US US11/812,673 patent/US20080139636A1/en not_active Abandoned
- 2007-12-19 CY CY20071101609T patent/CY1107838T1/el unknown
2008
- 2008-02-25 IL IL189758A patent/IL189758A0/en not_active IP Right Cessation
- 2008-12-04 US US12/314,156 patent/US20090176853A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PL355913A1 (en)	2004-05-31
IL150124A0 (en)	2002-12-01
ES2294219T3 (es)	2008-04-01
EE05134B1 (et)	2009-02-16
CA2393352C (en)	2011-08-30
IS6406A (is)	2002-05-31
JP2005320340A (ja)	2005-11-17
SK286987B6 (sk)	2009-08-06
CY1106602T1 (el)	2012-01-25
EP1352896B1 (en)	2007-10-31
NZ519378A (en)	2004-02-27
DE60009147T2 (de)	2005-04-21
EP1352897A3 (en)	2003-12-03
BRPI0016395B8 (pt)	2021-05-25
HK1057035A1 (en)	2004-03-12
ES2282546T3 (es)	2007-10-16
HK1046678B (en)	2004-12-03
DK1352895T3 (da)	2007-06-11
CO5251381A1 (es)	2003-02-28
AU2005202321A1 (en)	2005-06-23
BR0016395A (pt)	2002-08-27
EP1352897A2 (en)	2003-10-15
CY1107838T1 (el)	2013-06-19
ATE376994T1 (de)	2007-11-15
EP1352895B1 (en)	2007-03-28
PT1242364E (pt)	2004-07-30
DE60036968D1 (de)	2007-12-13
DE60032823D1 (de)	2007-02-15
KR20020061646A (ko)	2002-07-24
MY125978A (en)	2006-09-29
CY1106357T1 (el)	2011-10-12
DE60036968T2 (de)	2008-08-14
PT1352897E (pt)	2007-03-30
DK1352896T3 (da)	2008-01-28
NO20022856D0 (no)	2002-06-14
EE200200330A (et)	2003-10-15
US7132457B2 (en)	2006-11-07
SI1352895T1 (sl)	2007-08-31
SK8412002A3 (en)	2003-02-04
MXPA02005789A (es)	2002-09-18
EP1242364B1 (en)	2004-03-17
EP1352896A2 (en)	2003-10-15
US7297818B2 (en)	2007-11-20
EP1352895A2 (en)	2003-10-15
EP1352896A3 (en)	2003-12-03
EP1352897B1 (en)	2007-01-03
ATE261933T1 (de)	2004-04-15
PL200836B1 (pl)	2009-02-27
IS2246B (is)	2007-06-15
EP1862451A1 (en)	2007-12-05
DK1242364T3 (da)	2004-06-21
ATE350364T1 (de)	2007-01-15
NO20022856L (no)	2002-08-16
US6881754B2 (en)	2005-04-19
CN1434794A (zh)	2003-08-06
KR100710110B1 (ko)	2007-04-20
WO2001044170A1 (en)	2001-06-21
KR20070012883A (ko)	2007-01-29
PT1352895E (pt)	2007-05-31
ATE358117T1 (de)	2007-04-15
ES2215777T3 (es)	2004-10-16
NO328682B1 (no)	2010-04-26
DE60034155T2 (de)	2007-12-13
DE60034155D1 (de)	2007-05-10
DE60032823T2 (de)	2007-11-08
JP2003517035A (ja)	2003-05-20
AU2244401A (en)	2001-06-25
CN1312120C (zh)	2007-04-25
AU2005202321B2 (en)	2008-05-22
PT1352896E (pt)	2007-12-19
US20070082957A1 (en)	2007-04-12
AU780506B2 (en)	2005-03-24
US20080139636A1 (en)	2008-06-12
US20050049303A1 (en)	2005-03-03
HK1046678A1 (en)	2003-01-24
TR200401432T4 (tr)	2004-08-23
HUP0300616A2 (hu)	2003-07-28
DE60009147D1 (de)	2004-04-22
EP1242364A1 (en)	2002-09-25
EP1352895A3 (en)	2003-12-03
HUP0300616A3 (en)	2004-08-30
IL189758A0 (en)	2008-06-05
TWI258462B (en)	2006-07-21
JP3710418B2 (ja)	2005-10-26
US20030013704A1 (en)	2003-01-16
DK1352897T3 (da)	2007-04-10
ES2279031T3 (es)	2007-08-16
CZ20022093A3 (cs)	2003-01-15
US20090176853A1 (en)	2009-07-09
AR035325A1 (es)	2004-05-12
CA2393352A1 (en)	2001-06-21

Publication	Publication Date	Title
BR0016395B1 (pt)	2013-10-08	Derivados de adamantano
EE200100525A (et)	2002-12-16	Adamantaani derivaadid
EE200200295A (et)	2003-08-15	Adamantaani derivaadid
NO20000885D0 (no)	2000-02-23	4-Fenyl-pyridin-derivater
NO20021077L (no)	2002-03-05	Amino-triazolopyridin-derivater
DE50010060D1 (de)	2005-05-19	Thiazolylamid-derivate
IS6128A (is)	2001-10-26	13-Metýl-erýþrómýsín afleiður
DK1187814T3 (da)	2004-12-20	5-phenyl-pyrimidinderivater
NO20021803L (no)	2002-06-17	Isoksazolkarboksamid-derivater
ATE257148T1 (de)	2004-01-15	Propargyletherderivate
PT1154988E (pt)	2004-12-31	Derivados de mevinolina
ATE374747T1 (de)	2007-10-15	Monofluoralkylderivate
PT1187815E (pt)	2006-06-30	Derivados de 4-fenil-pirimidina
DE60006703D1 (de)	2003-12-24	4-hydroxybiphenylhydrazid-derivate
ATE293592T1 (de)	2005-05-15	Resorcinderivate
PT1088818E (pt)	2005-03-31	Derivados de quinolin-4-ilo
DE60025348D1 (de)	2006-03-30	Ethansulfonyl-piperidin-derivate
PT1194401E (pt)	2004-02-27	Derivados de diacil-hidrazina
NO20020212L (no)	2002-01-15	3-amino-2-benzyl-1-fenyl-propanderivater
NO20022867D0 (no)	2002-06-14	Syklopentenon-derivater
DK1178984T3 (da)	2003-06-10	1-trifluormethyl-4-hydroxy-7-piperidinylaminomethylchroman-derivater
ATE269328T1 (de)	2004-07-15	1-cycloalkylpyrazolyl-benzoyl-derivate

Legal Events

Date	Code	Title	Description
2009-10-27	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2010-08-10	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2011-01-11	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]	Free format text: DE ACORDO COM ART. 34 " II " DA LPI ( LEI 9279, DE 14/05/96 ) , O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.
2012-01-31	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2013-04-16	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2013-09-10	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2013-10-08	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2013, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/12/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2021-06-01	B21A	Patent or certificate of addition expired [chapter 21.1 patent gazette]	Free format text: PATENTE EXTINTA EM 12/12/2020